Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

ILYM17121 / Verastem / Carla Casulo

Research Question:
What is the effect of oral medicine, duvelisib, in patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL)?

Basic Study Information

Purpose:
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL).

Location: University of Rochester Medical Center
Study Reference #: ILYM-17121

Lead Researcher (Principal Investigator)

Lead Researcher:  Carla Casulo

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search